500
Participants
Start Date
December 13, 2024
Primary Completion Date
December 31, 2029
Study Completion Date
December 31, 2029
Ocrelizumab
Ocrelizumab will be administered according to the regimen in the parent study.
RECRUITING
Mun.Med.Proph.Inst.?Chernihiv Reg.Hosp.?, Chernihiv
RECRUITING
CHU De Caen, Caen
RECRUITING
5th Cherkasy City Center of Primary Health Care, Cherkasy
RECRUITING
Studienzentrum Nordwest Dr med Joachim Springub Herr Wolfgang Schwarz, Westerstede
RECRUITING
GroupeHospitalo-Universitaire Caremeau, Nîmes
RECRUITING
Groupe Hospitalier Pellegrin, Bordeaux
RECRUITING
Hopital Gui de Chauliac, Montpellier
RECRUITING
SI USSRI of Medical and Social Problems of Disabilities of MOHU, Dnipro
RECRUITING
Bukovinsky SMU RMI Chernivtsi RCH, Chernivtsi
RECRUITING
Hopital Gabriel Montpied CHU de Clermont-Ferrand, Clermont-Ferrand
RECRUITING
Deutsche Klinik für Diagnostik, Wiesbaden
RECRUITING
"LCC Medical center Unimed", Zaporizhzhia
RECRUITING
Municipal Non-profit Enterprise Zaporizhzhya Regional Hospital Zaporizhzhya Regional Council, Zaporizhzhia
RECRUITING
Hopital neurologique Pierre Wertheimer - CHU Lyon, Bron
RECRUITING
Regional Clinical Hospital, Ivano-Frankivsk
RECRUITING
Lvivska oblasna tsentralna likarnia, Lviv
RECRUITING
CHU Amiens Hopital Sud, Amiens Cedex1
RECRUITING
NeuroPoint Gesellschaft fur vorbeugende Gesundheitspflege mbH, Ulm
RECRUITING
Hôpital Pasteur, Nice
RECRUITING
Medical Center Dopomoga Plus, Kyiv
RECRUITING
Medical Center of Private Execution First Private Clinic, Kyiv
Hoffmann-La Roche
INDUSTRY